Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 extension study of regorafenib for participants from prior Bayer regorafenib trials
jRCT2031230602Phase 2Active, not recruiting
- Sponsor
- Bayer
- Start
- Mar 2024
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of regorafenib in Nonhematologic neoplasms (2 arms), sponsored by Bayer. Primary endpoint: Number of participants with serious adverse events (SAEs) and protocol-specified adverse events and their severity. Started Mar 2024; status: active, not recruiting.
02
Drugs
regorafenib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031230602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230602.